Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment

Table 2

Patient characteristics.

Variable		Patients included	Patients excluded due to inconsistent DCE data
N		758	140
Age in years, median, mean (SD)		72, 71.4 (9.9)	77, 74.4 (10.0)
Female gender, n (%)		324 (42.7)	60 (42.9)
BMI, median, mean (SD)
Male		27, 28.1 (4.7)	27, 27.8 (5.8)
Female		26, 27.5 (5.6)	26, 26.5 (5.5)
Country, n (%)
Germany		280 (36.9)	42 (30.0)
France		338 (44.6)	62 (44.3)
UK		140 (18.5)	36 (25.7)
AF duration in years, median, mean (SD)		3, 5.5 (6.4)	4, 5.7 (6.1)
Duration of current NOAC treatment in years, median, mean (SD)		2, 2.1 (1.7)	2, 2.4 (2.0)
Current anticoagulant, n (%)
Apixaban	2.5 mg	73 (9.6)	17 (12.1)
	5 mg	185 (24.4)	32 (22.9)
Edoxaban	30 mg	11 (1.5)	1 (0.7)
	60 mg	39 (5.2)	4 (2.9)
Dabigatran	110 mg	50 (6.6)	8 (5.7)
	150 mg	60 (7.9)	8 (5.7)
Rivaroxaban	15 mg	97 (12.8)	21 (15.0)
	20 mg	243 (32.1)	49 (35.0)
Frequency of administration, n (%)
Apixaban	Once daily	2 (0.3)	0 (0.0)
	Twice daily	256 (33.8)	49 (35.0)
Edoxaban	Once daily	50 (6.6)	5 (3.6)
	Twice daily	0 (0.0)	0 (0.0)
Dabigatran	Once daily	2 (0.3)	0 (0.0)
	Twice daily	108 (14.2)	16 (11.4)
Rivaroxaban	Once daily	340 (44.9)	70 (50.0)
	Once daily	0 (0.0)	0 (0.0)
Patients previously prescribed with OAC, n (%)		50 (6.6)	9 (6.4)
Currently taking other prescription medications regularly, n (%)		720 (95.0)	134 (95.7)
Number of different medications, median, mean (SD)		3, 4.0 (2.9)	4, 4.6 (2.9)
Comorbidities, n (%)
Heart failure		224 (32.2)	53 (37.9)
Hypertension		472 (62.3)	75 (53.6)
Diabetes		166 (21.9)	31 (22.1)
Stroke		75 (9.9)	20 (14.3)
Impaired kidney function		65 (8.6)	15 (10.7)
Vascular disease		95 (12.5)	23 (16.4)
Type of primarily treating physician, n (%)
GP		220 (29.0)	51 (36.4)
Cardiologist		627 (82.7)	110 (78.6)
Others		27 (3.6)	2 (1.4)

statistically significant at .